EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments. The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company announced it received a grant to develop a new and unique vaccine with the goal of eradicating polio. This provides further proof of the scientific community's belief in the EVAX approach.